Final Analysis of a Noninterventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N)
-
Published:2024-07
Issue:
Volume:
Page:102159
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Viktor GrünwaldORCID,
Martin Bögemann,
Mohammad-Reza Rafiyan,
Günter NiegischORCID,
Marco Schnabel,
Anne FlörckenORCID,
Michael Maasberg,
Christoph Maintz,
Mark-Oliver Zahn,
Anke WortmannORCID,
Andreas Hinkel,
Jochen Casper,
C Darr,
Thomas Hilser,
M Schulze,
Disorn Sookthai,
Philipp Ivanyi
Reference21 articles.
1. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib;Motzer;New Eng J Med,2014
2. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939. doi:10.1016/s0140-6736(11)61613-9
3. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet,2008
4. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer;Eichelberg;Eur Urol,2015
5. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial;Choueiri;Lancet Oncol,2016